What does it do?
Astrana Health is a hypergrowth healthcare company that earns money by managing patient care through value-based contracts with health insurers. The company operates a physician-centric model where it receives a fixed monthly payment per patient, known as capitation, to manage all or part of their medical needs. Instead of being paid for each visit or procedure, Astrana is rewarded for keeping patients healthy and reducing expensive hospital stays. Its proprietary AI-powered technology platform handles everything from claims processing to clinical data analysis, helping its network of 20,000 providers identify high-risk patients before they require emergency care.
Where does revenue come from?
Nearly 96% of revenue comes from the Care Partners segment, which manages value-based care arrangements for over a million members. The remaining revenue is split between Care Delivery, which operates company-owned clinics, and Care Enablement, which provides administrative and technology services to third-party medical groups. Geographically, the company has historically been concentrated in California but is rapidly expanding its footprint into markets like Texas, Nevada, and Hawaii through recent acquisitions and partnerships.
Revenue Breakdown
Who are its customers?
Astrana Health manages care for approximately 1.5 million members while supporting a network of more than 20,000 affiliated providers. This dual-sided customer base includes large health insurance payers who outsource their risk to Astrana and independent physicians who join Astrana's network to access its technology and contracting power. In the second quarter of 2026, the company added approximately 3,000 new Medicare Advantage professional-risk lives in Texas alone. Membership has scaled significantly following the July 2025 acquisition of Prospect Health, which added substantial scale to its California and Texas operations.
What gives it staying power?
Astrana's staying power comes from its deep physician alignment and the high switching costs of its technology-integrated provider network. Once a medical group integrates Astrana's AI-native operating system into its workflow, moving to a competitor would disrupt patient data and complex risk-sharing contracts.
Where is it headed?
The company is aggressively transitioning its membership base into full-risk arrangements, which currently account for about 42% of its total members. Management is betting that its AI-native platform can manage medical costs more effectively than rivals, allowing Astrana to keep a larger portion of the savings as these contracts mature.
Revenue is accelerating sharply as the business expands its geographic footprint and membership base. Total revenue grew 49% year-over-year in the second quarter of 2026 to $972.5 million, primarily driven by organic growth and the successful integration of Prospect Health.
Cash generation is healthy with free cash flow of $92.9 million in the first half of 2026 representing roughly 69% conversion of adjusted EBITDA. The company is effectively turning its accounting profits into usable cash, though interest expense has doubled recently due to the debt taken on for acquisitions.
The balance sheet carries $882.7 million in long-term debt but remains resilient with a net leverage ratio that has improved to 2.3 times EBITDA. Management has shown discipline by paying down over $100 million in debt during the first half of 2026 while maintaining a cash balance of $400.8 million.
Astrana Health is a financially strong business in a rapid scaling phase that is successfully translating massive revenue growth into record-high earnings per share.
Astrana Health does not pay a regular dividend and instead prioritizes using its cash for debt repayment and strategic acquisitions. While the company occasionally pays small dividends to non-controlling interests in its subsidiaries, it spent $4.4 million on share buybacks in the first half of 2026. The share count has remained relatively flat over the last year as buybacks offset stock-based compensation, meaning an owner's slice of the business is holding steady. This is a growth holding where investors should expect returns from business expansion rather than quarterly cash checks.
The Care Enablement segment grew revenue by 109% this quarter, proving that third-party providers are increasingly willing to pay for Astrana's technology platform. This high-margin segment helps offset the volatility of medical costs in the risk-bearing divisions and demonstrates the scalability of the company's AI-native operating system.
Medical cost volatility remains the primary risk, as a 5.2% annual cost trend could compress margins if not managed strictly by the AI platform. Management must prove it can maintain its 7% adjusted EBITDA margin even as it expands into newer, less mature markets where it has less historical patient data.
The value-based healthcare management market is roughly $500 billion today and is on track to exceed $800 billion by 2031 as insurers move away from fee-for-service models. This industry rewards companies that can hold prices while lowering medical costs through better patient management. Astrana Health stands as a leading physician-centric challenger in this market, using its technology to manage risk more efficiently than traditional hospital-led systems.
The competitive dynamic in value-based care is increasingly intense as massive insurers like UnitedHealth and CVS acquire physician groups to build their own networks. Scale and data are the primary forces shaping long-term pricing power in this industry.
Astrana faces its most direct threat from Optum, which uses its nearly unlimited capital and insurance data to lock up physician groups at scale. Privia Health and Agilon Health compete for the same independent doctor groups by offering similar technology platforms, but they often take less risk than Astrana. The most dangerous threat comes from large insurers who can internalize these management functions, potentially removing Astrana's role as a middleman.
Astrana Health is currently gaining share, with revenue up 49% this quarter while maintaining steady 7% EBITDA margins. The company is successfully winning large physician groups in new markets like Texas and Hawaii.
Astrana's primary source of protection is its network effect, where 20,000 providers and 1.5 million members feed a data engine that improves medical cost management for everyone in the system. As the network grows, the AI-native operating system gets better at predicting health risks, which lowers the cost of care and attracts more insurers. This data-driven physician lock-in makes it difficult for rivals to displace Astrana once a medical group is integrated.
The company's financials prove the durability of this advantage, with G&A expenses dropping to 6% of revenue as the technology handles more of the administrative load. While the net margin of 1.1% looks thin, it reflects the heavy investment in growth and the massive revenue through-put of the risk-bearing model. Astrana's success in generating $120.4 million in gross shared savings in 2024 proves its model can extract real value from the healthcare system.
The moat is strengthening as the company deepens its technological integration into provider workflows. The 50% reduction in claims handling time is a concrete signal that Astrana is building a cost advantage that will be difficult for less automated rivals to match.
Integration of Prospect Medical assets is proceeding ahead of management's original schedule.
Paid down over $100 million in debt in the first half of 2026.
CEO Brandon Sim has overseen a transformational growth period with record adjusted EPS.
Capital Allocation Track Record
Management has demonstrated exceptional strategic judgment by pivoting the company toward a technology-first, AI-native operating model while successfully integrating a transformational $675 million acquisition. CEO Brandon Sim has maintained a disciplined focus on capital allocation, prioritizing debt repayment and high-return geographic expansion over dilutive growth. The team has built high credibility with investors by consistently raising guidance, including the recent increase in full-year 2026 adjusted EBITDA expectations.
Governance risk is moderate as the company is led by a relatively young CEO whose vision is central to the technology-driven strategy. While there is a strong bench of senior leaders including Daniel Rothman and Vishal Gupta, the rapid pace of expansion and ongoing legal investigations require focused leadership to avoid operational stumbles. The recent strengthening of the executive team with enterprise transformation specialists suggests a proactive approach to managing the risks of a much larger, multi-state organization.
We expect revenue to grow from $4.0B in FY2026 to $6.0B in FY2031 (~9% CAGR), with EPS growing from $1.40 to $4.36 (~26% CAGR). Growth is driven by expanding the provider network into new geographic markets and taking share from traditional fee-for-service models as more patients move into risk-sharing contracts. Profits improve as the company better manages medical costs in newer regions and spreads its central technology costs over a larger patient base. EPS grows faster than revenue because profit margins are expected to recover from recent lows as the business scales. Operating margin expected to reach ~6% by FY2031.
Maturation of full-risk cohorts drives significant margin expansion. As newer members move into full-risk arrangements, Astrana captures more of the insurance premium and reduces medical costs through its technology.
Geographic expansion into Texas and Hawaii scales the platform. Successfully replicating the California model in new states proves the AI platform is truly geographic-agnostic and scalable.
Care Enablement segment scales high-margin technology revenue. Selling its AI-native operating system to third-party providers provides a high-margin, capital-light revenue stream that balances insurance risk.
Medical cost inflation spikes above fixed capitation payments. If hospital and drug costs rise faster than the rates set in insurer contracts, Astrana's profit margins could disappear quickly.
Legal investigations into securities law violations lead to material penalties. Ongoing probes by multiple law firms could lead to costly litigation or damage the company's reputation with physician partners.
Integration of Prospect Health assets faces unexpected operational hurdles. Any failure to achieve expected synergies from the $675 million acquisition would strain the balance sheet and slow expansion.
Below is our estimate of current and future fair value, with detailed reasoning and assumptions. Fair value is a judgment, not a fact, and other analysts will likely land on different numbers. Use it as one data point in your research, and apply your own discretion in any investing decision.
We value Astrana Health based on its estimated earnings five years from now, discounted back to what that value is worth today. This method fits a business that is currently spending heavily to integrate acquisitions and shift its contract model, as today's thin profits don't yet show the true earning power of the completed platform.
We calculated that the company will earn $4.36 per share in 2031 and applied a 30x multiple to reach a future price of $131, which is worth $83 today. Our 30x multiple is lower than the 42x investors pay for the stock today and below its five-year average of 35x, reflecting a more mature and stable business by 2031. For comparison, rivals like Privia Health often trade at even higher levels when growth is strong, but we chose 30x to be careful. The final $83 value includes the present value of all profits earned between now and then, discounted at 10% per year.
Priced instead on what investors pay for next year's earnings at a 40x multiple, we get a value of $79 — very close to our $83 result. We arrived at this by taking the $1.97 per share the company is expected to earn in 2027 and multiplying it by 40x, which is just below the 42x it trades at right now. Rivals like UnitedHealth or Humana trade at lower multiples because they are much larger and slower-growing, while smaller, high-growth medical managers typically command 40x to 50x. The fact that both methods land within 5% of each other gives us more confidence that the $80 range is the right target.
The biggest risk is a regulatory or legal ruling that challenges how the company bills for its value-based care services. This would force the company to change its operating model, likely dropping the price investors are willing to pay for each dollar of profit from 30x to 18x and knocking roughly $33 off the per-share fair value. Watch for updates on the ongoing securities law investigations for any signals of structural billing issues.
Bear case ($50): Regulatory changes to ACO REACH or Medicare Advantage significantly reduce the profit potential of full-risk contracts; or Medical costs spike above 6% for multiple quarters, proving that the company's AI tools cannot manage patient care as efficiently as expected.
Bull case ($115): The company expands its AI-powered platform to three new states within 24 months, proving the model can scale nationally; or Profit margins double as the integration of Prospect Health assets finishes early, delivering over $20 million in annual savings.
Clearthesis wrote this report from 40 sources, including SEC filings, analyst estimates, industry research, and recent news.
How did you like this thesis?
Your feedback helps us make reports better for you
© 2026 Clearthesis.ai · Report generated on September 24, 2026
This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.